查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1835568

偏頭痛治療市場（按藥物類別、給藥途徑、分銷管道、適應症和患者年齡層分類）—2025-2032 年全球預測

Migraine Drugs Market by Drug Class, Route Of Administration, Distribution Channel, Indication, Patient Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年偏頭痛藥物市場規模將成長至 183.4 億美元，複合年成長率為 16.28%。

主要市場統計數據
基準年2024年 54.8億美元
預計2025年 63.9億美元
預測年份：2032年 183.4億美元
複合年成長率（%） 16.28%

全面的介紹，為塑造現代偏頭痛治療格局的臨床創新、商業性動態和策略重點提供框架

隨著相關人員尋求更有效、更耐受的治療方案，偏頭痛持續受到臨床、監管和商業領域的關注。本執行摘要全面概述了偏頭痛藥物，整合了最新的臨床進展、不斷發展的治療模式以及影響製劑師整體情況的商業性反應。引言部分涵蓋了報告中探討的關鍵主題，包括藥物類別、給藥方式、分銷管道、不同年齡層的需求以及政府和貿易措施對藥物供應的影響。

此次重點市場研究的出發點在於快速的創新步伐和持續存在的未滿足需求。患者通常需要循環使用多種急性和預防性治療方案，而臨床醫生也越來越重視長期安全性、依從性和生活品質，而不僅僅是療效。因此，產品定位需要對新治療方法和成熟療法在配方和臨床環境中如何共存有細緻的理解。本報告整合了這些動態，以支援策略定位、臨床開發優先排序和商業化規劃。

為了確保與多方相關人員的相關性，引言還闡明了報告的範圍、用於三角證據檢驗的方法以及用戶可獲得的可交付成果類型。引言為後續章節提供了背景資訊，確保能夠在連貫的分析框架內解讀跨藥物類別、給藥途徑、分銷策略、患者細分和區域差異的比較考慮。

作用機制、監管應用和數位化護理的突破性進展正在重新定義偏頭痛藥物的開發、取得和商業化

由於科學突破、監管變革以及患者和付款人期望的不斷變化，偏頭痛藥物治療領域正在發生重大變化。針對降鈣素基因相關胜肽（CGRP）通道的生技藥品的進展正在重新定義預防性治療，而小分子調節劑和選擇性血清素受體激動劑的出現則拓展了急性治療的選擇。這些治療方法創新正在改變臨床治療方案，迫使臨床醫生重新評估長期以來的配藥習慣，並引入耐受性更高、給藥更便捷的促效劑。

隨著藥理學的進步，監管機構正在適應更短的研發週期和新的終點指標，這些指標旨在捕捉以患者為中心的結果，例如減少頭痛相關的殘疾和改善日常功能。為了因應這些變化，付款人和製劑委員會正在製定證據要求，強調現實世界的有效性和成本效益，而非短期臨床終點。因此，製造商越來越重視核准後的觀察性研究和基於價值的合約。

商業模式也在改變。數位健康工具、遠端監控和遠端醫療正在增強病人參與和依從性，並為結合治療和服務的一體化照護模式創造機會。此外，製造商正在嘗試差異化的報銷方式和有針對性的教育宣傳活動，以促進特定患者群體的合理用藥。總而言之，新的作用機制、不斷變化的監管預期、支付方主導的證據需求以及數位化正在改變偏頭痛藥物的開發、定位和交付方式。

評估 2025 年美國關稅調整對供應鏈、成本和採購的累積影響及其對偏頭痛藥物供應和商業規劃的影響

關稅措施可能對藥品流通和跨境供應鏈的經濟性產生重大影響。美國近期對2025年關稅表的修改，對採購、分銷和定價策略帶來了連鎖反應。擁有全球供應足跡的製造商必須重新評估採購決策，評估替代物流管道，並規劃變動到岸成本，這些成本將影響與批發商和綜合分銷網路的合約談判。在許多情況下，製造商和經銷商正在重新評估其庫存策略，以降低進口關稅逐步調整的風險。

從商業性角度來看，關稅波動可能會導致某些管道的產品供應短期中斷，也可能會隨著企業適應調整的成本結構而改變促銷活動的時機。對於依賴複雜低溫運輸物流或特殊包裝且面臨更嚴格海關審查的治療藥物而言，這些動態可能特別嚴重。因此，跨職能團隊正在將關稅情境納入其情境規劃中，以在維持供應連續性的同時，維持利潤率的完整性。

在監管和政策方面，相關人員正在與行業協會合作，明確分類代碼，在適用的情況下爭取優惠待遇，並倡導簡化處方藥的清關流程。同時，醫療保健支付方和機構買家正​​在重新調整其採購框架，以確保韌性，並青睞那些擁有健全緊急時應對計畫和透明成本轉嫁機制的供應商。關稅調整的累積影響正在推動偏頭痛藥物產業在供應鏈設計和商業執行方面採取更具策略性和風險意識的方法。

深入了解藥品類別、給藥方式、分銷管道、適應症和年齡層，從而實現策略優先排序和差異化

分段分析揭示了在確定開發重點時臨床和商業重要性，包括按藥物類別、給藥途徑、分銷管道、適應症和患者人口統計進行分析。依藥物類別，研究了 CGRP 單株抗體、達坦衍生物、麥角類似物、gepants、非類固醇抗發炎藥和曲坦類藥物。在 CGRP 單株抗體中，分析了 eptinezumab、erenumab、fremanezumab 和 galcanezumab；在達坦衍生物中，分析了 lasmiditan；在麥角類似物中，分析了Dihydroergotamine和麥角胺；在 gepants 中，分析了 atogepant、rimegepant 和麥角胺； ubrogepant；在非類固醇消炎劑中，分析了Ibuprofen和萘普生；在曲坦類藥物中，阿莫曲坦、依來曲坦、夫羅曲坦、Rizatriptan、利扎曲Sumatriptan和佐米曲坦都被納入考量。此分類有助於比較和評估跨管道的機制療效、安全性、給藥頻率和付款人期望。

依給藥途徑，藥物可分為注射劑、鼻腔給藥、口服、外用及經皮給藥。注射劑又分為靜脈注射和皮下注射，口服藥物又分為膠囊和錠劑。給藥途徑會影響患者的依從性、用藥負擔以及診所和居家照護模式之間的差異。分銷管道細分區分了線下和線上路徑，反映了不同的購買行為、複合訪問模式和數位化互動機會，這些因素會影響藥物的吸收速度和依從性支持。

適應症細分區分急性治療和預防性治療，突顯臨床研究設計、終點選擇和報銷標準的差異。患者年齡細分涵蓋成人和兒童族群，兒科分析進一步細分為青少年、兒童和新生兒，以考慮特定年齡的安全性、劑量和給藥途徑。結合使用這些細分視角，可以深入了解臨床差異化、商業性投資和監管重點。

區域戰略要務強調監管差異、付款人期望和醫療保健基礎設施如何影響全球市場的採用和准入

區域動態對臨床應用、監管時間表、報銷框架和商業性執行有重大影響，美洲、歐洲、中東和非洲以及亞太地區呈現出明顯的區域差異。在美洲，成熟的專科護理網路、較高的生技藥品採用率以及不斷發展的支付方框架，創造了一種良好的環境，使得有堅實實現實世界證據和價值證明支持的新型預防療法能夠迅速應用於臨床實踐。該地區的相關人員在製定配方決策時通常優先考慮長期療效和患者報告指標，這使得製造商能夠透過使證據產生與支付方期望一致來加速藥物的採用。

在歐洲、中東和非洲，監管多樣性和報銷模式的多樣性決定了產品的上市順序和定價策略。國家衛生技術評估機構和集中監管管道發揮重要作用，要求製造商調整參與策略，以協調臨床效益和成本效益評估。同時，由於基礎設施的多樣性，中東和北非市場可能面臨准入挑戰，這凸顯了創新經銷夥伴和能力建設的必要性。

亞太地區專科成熟度和支付方成熟度呈現廣泛頻譜，部分市場在本地臨床數據和可負擔性計畫支持下，迅速接受了新型療法。由於當地監管要求和醫療資金籌措的多樣性，市場進入計劃也需要調整，包括在地化生產、分級定價以及與本地經銷商合作。總體而言，每個區域的洞察都強調了根據其獨特的結構特徵客製化證據生成、商業模式和供應鏈韌性的重要性。

競爭性和策略性的企業行動將決定不斷發展的偏頭痛治療市場的准入、吸收和長期定位

偏頭痛治療領域公司之間的競爭動態反映了各種策略，從產品組合廣度和生命週期管理到有針對性的創新和夥伴關係。大型生物製藥公司憑藉其成熟的商業平台和對長期實證項目的投資，在預防醫學領域佔據強勢地位。這類公司通常奉行廣泛的適應症策略，並結合病患支援計畫和整合服務，以促進病患依從性和專業配藥。

利基市場和中端市場公司專注於特定患者群體，這些群體憑藉著差異化的作用機制、便捷的給藥方式和臨床差異化，獲得了高階定位。創新者與製造外包和分銷合作夥伴之間的夥伴關係日益普遍，這不僅促進了供應鏈的敏捷擴張，也使規模較小的公司能夠專注於臨床開發和打入市場策略。製藥公司與數位醫療供應商之間的策略聯盟也在不斷增多，這反映出一種趨勢：轉向將藥物管理與依從性和監測工具相結合的捆綁式提案。

縱觀競爭格局，那些展現清晰證據藍圖、彈性價格設定方式以及與專科網路和付款人建立牢固關係的公司更有可能獲得良好的可及性結果。此外，那些積極管理方案轉換模式、最佳化患者啟動管道，並以簡潔、注重結果的資料集支持臨床醫生的公司，更有能力實現持續應用。觀察這些策略行為，可以為尋求改善市場進入和擴張策略的公司提供實用範本。

可行的策略建議，將證據生成、數位化支持和彈性商業模式結合起來，以確保永續的獲取和採用

尋求在偏頭痛藥物中獲取永續價值的行業領導者應採取多管齊下的方法，將臨床證據、付款人參與度和營運韌性融為一體。首先，優先產生以患者為中心的真實世界數據，這些數據可以補充隨機對照試驗的結果，並直接解答付款人關於療效持久性、異質人群安全性以及健康經濟結果的疑問。此類證據將有助於支持以金額為準的對話，並確保處方集的有利定位。

第二，開發差異化的病患支持和依從性項目，利用數位化工具減少治療啟動和持續性的障礙。整合臨床醫生教育、遠端監控和簡化的就診流程的一體化護理路徑，顯著提高了治療的連續性和患者滿意度，強化了臨床和經濟價值提案。第三，制定靈活的商業策略，將區域監管差異和與關稅相關的供應鏈風險納入考量。這可以包括多元化製造和分銷合作夥伴、投資本地監管專業知識，並將關稅情境納入情境規劃。

最後，在可行的情況下，並有強力的結果指標支持的情況下，尋求與付款人和醫療系統合作，例如成果合約和風險共擔模式。此類夥伴關係可以加速藥物的可及性，同時圍繞可衡量的患者利益調整獎勵。綜上所述，這些行動可以支持一種有韌性的、以證據主導的市場進入和生命週期管理方法，平衡短期吸收和長期價值實現。

透過結合主要相關人員訪談、系統性文獻回顧和交叉檢驗分析方法的嚴格、多源調查方法來獲得可行的見解

支撐本分析的調查方法整合了多種證據流，以確保獲得穩健的、三角化的洞察。主要研究包括對臨床醫生、付款人、採購專業人員和行業高管進行結構化訪談，以了解關於治療方法選擇、製劑決定因素和營運障礙的實際經驗。次要研究包括對同行評審文獻、監管文件、臨床試驗註冊中心和上市公司資訊揭露進行系統性回顧，以檢驗臨床概況、安全訊號和產品平臺。

分析方法包括：將定性輸入與二級資訊來源進行交叉驗證；對訪談進行主題編碼以識別反覆出現的障礙和促成因素；以及開發細分矩陣以映射臨床效用和商業性槓桿。供應鏈和關稅影響評估利用關稅分類、物流工作流程和專家諮詢來模擬潛在的營運反應，但不預測具體的市場規模。品質保證流程包括治療領域專家的同儕審查以及透過後續訪談核對資料差異。

本調查方法整合多元證據，並運用清晰的分析邏輯，記錄所提出見解和建議背後的邏輯。這種方法在深度與實用性之間取得平衡，旨在為需要可操作情報而非僅僅提供高深概述的決策者提供資訊。

簡潔的結論綜合了現代偏頭痛治療領域成功的創新、獲取動態和策略重點

最後，偏頭痛治療領域的特點是意義深遠的科學進步、不斷發展的商業模式，以及支付方和患者對可衡量療效的期望不斷提高。生物預防藥物、用於急性治療的標靶小分子藥物以及輔助性數位化工具的融合正在重塑治療標準，並迫使相關人員採用更複雜的價值驗證策略。在這種環境下取得成功，需要在臨床差異化、證據產生和切實可行的商業性執行之間實現清晰的協調。

製造商和投資者應將此視為一個機遇，從嚴謹的證據規劃、敏捷的供應鏈策略和建設性的付款人參與中獲益，而臨床醫生和患者權益倡導者將受益於一個不斷擴展的治療套件，該工具包可根據患者的個體偏好和耐受性要求進行客製化。隨著該行業的發展，對現實世界結果、依從性支持和協作可及模式的持續關注將決定哪些創新能夠帶來患者照護的顯著改善。

綜上所述，本執行摘要中的見解為立即行動和長期規劃提供了基礎。相關人員若能運用此觀點來完善其開發策略、最佳化其開發方法並增強經營體質，將更有能力掌握正在進行的偏頭痛治療創新的臨床和商業性潛力。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • CGRP單株抗體治療偏頭痛的快速應用以及保險報銷的挑戰
  • 用於緩解和預防急性偏頭痛的口服 Gepants（CGRP 受體拮抗劑）的市場滲透率正在擴大
  • 現實世界證據的快速成長將影響新的健康保險覆蓋範圍和處方箋決策
  • 將數位療法和穿戴式監測平台整合到個人化慢性偏頭痛管理計畫中
  • 非侵入性神經刺激設備的進步為難治性偏頭痛患者提供了更多的非藥物治療選擇
  • 昂貴的偏頭痛生技藥品的生物學名藥的開發可能會擾亂定價和市場競爭
  • 與高成本偏頭痛藥物的付款人簽訂基於價值和基於績效的契約
  • 關注健康公平舉措，以提高醫療資源匱乏人群獲得先進偏頭痛藥物的途徑和可負擔性
  • 擴展遠端醫療平台，加速偏頭痛藥物的虛擬診斷、遠端系統管理和患者支持

第6章 2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：偏頭痛藥物市場（依藥物類別）

  • Cgrp單株抗體
    • 依替尼珠單抗
    • 埃雷努馬布
    • 弗雷曼珠單抗
    • 加卡尼珠單抗
  • 距離
    • 拉斯米迪坦
  • 麥角衍生物
    • Dihydroergotamine
    • 麥角胺
  • 同性戀褲子
    • 阿托格潘特
    • 裡梅格潘特
    • 烏布羅格潘特
  • NSAIDs
    • 雙氯芬酸鈉
    • Ibuprofen
    • 萘普生
  • 曲坦類
    • 阿莫曲坦
    • 依來曲坦
    • 芙羅曲坦
    • 那拉曲坦
    • Rizatriptan
    • Sumatriptan
    • 佐米曲坦

第9章 偏頭痛治療市場（依給藥途徑）

  • 注射
    • 靜脈
    • 皮下
  • 鼻腔
  • 口服
    • 膠囊
    • 藥片
  • 局部的
  • 經皮

第 10 章偏頭痛治療市場（依通路）

  • 離線
  • 線上

第 11 章 偏頭痛治療市場（依適應症）

  • 急性治療
  • 預防性治療

第 12 章 偏頭痛治療市場（依患者年齡層分類）

  • 成人
  • 孩子們
    • 青年
    • 嬰兒
    • 新生

第13章 偏頭痛治療市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 偏頭痛治療市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第 15 章。按國家/地區分類的偏頭痛治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • AbbVie Inc.
    • Amgen Inc.
    • Novartis AG
    • Eli Lilly and Company
    • H. Lundbeck A/S
    • Biohaven Pharmaceutical Holding Company Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc
Product Code: MRR-036C5CF3A820

The Migraine Drugs Market is projected to grow by USD 18.34 billion at a CAGR of 16.28% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.48 billion
Estimated Year [2025] USD 6.39 billion
Forecast Year [2032] USD 18.34 billion
CAGR (%) 16.28%

A comprehensive introduction that frames clinical innovations, commercial dynamics, and strategic priorities shaping the contemporary migraine therapeutics environment

Migraine continues to command attention across clinical, regulatory, and commercial forums as stakeholders pursue more effective and better tolerated therapeutic options. This executive summary introduces a holistic view of the migraine drugs landscape that integrates recent clinical advances, evolving treatment paradigms, and the commercial responses that shape prescriber behavior. The introduction frames the core topics examined in the report: drug-class differentiation, administration modalities, distribution pathways, age-segmented needs, and the influence of policy and trade measures on availability.

The rationale for a focused market study is rooted in the rapid pace of innovation coupled with persistent unmet needs. Patients frequently cycle through multiple acute and preventive regimens, and clinicians increasingly weigh long-term safety, adherence, and quality-of-life outcomes alongside efficacy. Consequently, product positioning now requires a nuanced understanding of how novel modalities and established therapies coexist in formularies and clinical practice. The report synthesizes these dynamics to support strategic positioning, clinical development prioritization, and commercialization planning.

To ensure relevance for diverse stakeholders, the introduction also clarifies the report's scope, the methodological approach used for evidence triangulation, and the types of deliverables available to subscribers. By setting a clear context for subsequent sections, this introduction prepares readers to interpret comparative insights on drug classes, administration routes, distribution strategies, patient segmentation, and regional differentials within a coherent analytical framework.

How breakthroughs in mechanism of action, regulatory adaptation, and digital-enabled care are jointly redefining development, access, and commercialization in migraine therapeutics

The migraine treatment landscape is undergoing transformative shifts driven by scientific breakthroughs, regulatory evolution, and changing expectations among patients and payers. Advances in biologics targeting CGRP pathways have reframed preventive care, while the arrival of small-molecule modulators and selective serotonin receptor agonists has expanded options for acute management. These therapeutic innovations are altering clinical algorithms, prompting clinicians to re-evaluate long-standing prescribing habits and to incorporate newer agents where improved tolerability or administration convenience offers tangible benefits.

Alongside pharmacologic progress, regulatory pathways are adapting to accommodate accelerated development timelines and novel endpoints that capture patient-centered outcomes, such as reduction in headache-related disability and improvements in daily functioning. Payers and formulary committees are responding to these changes by developing evidence requirements that emphasize real-world effectiveness and cost-effectiveness over short-term clinical endpoints. As a result, manufacturers are placing greater emphasis on post-authorization observational research and value-based contracting.

Commercial models are also shifting. Digital health tools, remote monitoring, and telemedicine are strengthening patient engagement and adherence programs, thus creating opportunities for integrated care models that pair therapeutics with services. Moreover, manufacturers are experimenting with differentiated reimbursement approaches and targeted education campaigns to drive appropriate use among specific patient cohorts. In summary, the combined force of novel mechanisms of action, evolving regulatory expectations, payer-driven evidence demands, and digital enablement is transforming how migraine therapies are developed, positioned, and delivered.

Assessing the cumulative supply chain, cost, and procurement effects of United States tariff adjustments in 2025 and their implications for migraine drug availability and commercial planning

Tariff policy can materially affect the movement of pharmaceutical goods and the economics of cross-border supply chains, and recent changes in United States tariff schedules in 2025 introduced adjustments that ripple through procurement, distribution, and pricing strategies. Manufacturers with global supply footprints have had to reassess sourcing decisions, evaluate alternative logistics corridors, and plan for variable landed costs that influence contracting discussions with wholesalers and integrated delivery networks. In many cases, manufacturers and distributors are rebalancing inventory strategies to mitigate the risk of step changes in import duties.

From a commercial perspective, tariff shifts can create short-term disruptions to product availability in specific channels and may alter the timing of promotional activities as companies adapt to revised cost structures. These dynamics can be particularly acute for therapies that rely on complex cold-chain logistics or specialized packaging that incurs higher customs processing scrutiny. Consequently, cross-functional teams are integrating tariff scenarios into scenario planning to preserve margin integrity while maintaining supply continuity.

On the regulatory and policy front, stakeholders are engaging with trade and industry associations to clarify classification codes, secure preferential treatment where applicable, and advocate for streamlined customs processes for medical products. Meanwhile, payers and institutional buyers are recalibrating procurement frameworks to ensure resilience, favoring suppliers who demonstrate robust contingency planning and transparent cost pass-through mechanisms. Ultimately, the cumulative impact of tariff adjustments is prompting a more strategic, risk-aware approach to supply chain design and commercial execution in the migraine drugs sector.

Deep segmentation-driven insights that compare drug classes, administration modalities, distribution pathways, indications, and age cohorts to inform strategic prioritization and differentiation

Segment-level analysis reveals distinct clinical and commercial imperatives across drug classes, administration routes, distribution channels, indications, and patient age groups that shape prioritization for development and market access. By drug class, the landscape is studied across CGRP monoclonal antibodies, ditans, ergot derivatives, gepants, NSAIDs, and triptans, with CGRP monoclonals further analyzed by products such as eptinezumab, erenumab, fremanezumab, and galcanezumab, ditans centered on lasmiditan, ergot derivatives examined through dihydroergotamine and ergotamine, gepants reviewed across atogepant, rimegepant, and ubrogepant, NSAIDs considered through diclofenac, ibuprofen, and naproxen, and triptans explored via almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, and zolmitriptan. This taxonomy supports comparative assessment of mechanism-driven efficacy, safety profiles, dosing frequency, and pathway-specific payer expectations.

In terms of route of administration, the market is studied across injectable, nasal, oral, topical, and transdermal modalities, with injectables further broken down into intravenous and subcutaneous forms and orals differentiated between capsule and tablet presentations. Route considerations influence patient adherence, administration burden, and opportunities for clinic-based versus home-based care models. Distribution channel segmentation distinguishes offline and online pathways, reflecting distinct purchasing behaviors, formulary access patterns, and opportunities for digital engagement that affect uptake velocity and adherence support.

Indication segmentation separates acute treatment from preventive treatment, highlighting differences in clinical trial designs, endpoint selection, and reimbursement criteria. Patient age group segmentation covers adult and pediatric populations, with pediatric analysis further segmented into adolescents, children, and neonates to ensure age-appropriate safety, dosing, and route considerations. Together, these segmentation lenses enable nuanced insight into where clinical differentiation, commercial investment, and regulatory focus are most consequential.

Regional strategic imperatives revealing how regulatory heterogeneity, payer expectations, and healthcare infrastructure shape adoption and access across global markets

Regional dynamics profoundly influence clinical adoption, regulatory timelines, reimbursement frameworks, and commercial execution, with distinct patterns observable across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established specialty care networks, high rates of biologic uptake, and evolving payer frameworks create an environment where novel preventive treatments can rapidly integrate into clinical practice when supported by robust real-world evidence and value demonstration. Stakeholders in the region often prioritize long-term outcomes and patient-reported measures in formulary decisions, which can accelerate adoption when manufacturers align evidence generation with payer expectations.

In Europe, Middle East & Africa, regulatory heterogeneity and diverse reimbursement models shape launch sequencing and pricing strategies. National health technology assessment bodies and centralized regulatory pathways exert significant influence, prompting manufacturers to tailor entry strategies that reconcile clinical benefit with cost-effectiveness assessments. Meanwhile, markets across the Middle East and Africa may present access challenges due to infrastructural variability, emphasizing the need for innovative distribution partnerships and capacity building.

The Asia-Pacific region exhibits a wide spectrum of maturity in specialty care and payer sophistication, with several markets demonstrating rapid uptake of novel therapies when local clinical data and affordability programs support access. Local regulatory requirements and variations in healthcare financing necessitate adaptive market entry plans, including considerations for manufacturing localization, tiered pricing, and collaboration with regional distributors. Overall, regional insights underscore the importance of aligning evidence generation, commercial models, and supply-chain resilience with the unique structural characteristics of each geography.

Competitive and strategic company behaviors that determine access, uptake, and long-term positioning in the evolving migraine therapeutics market

Competitive dynamics among companies operating in the migraine therapeutics space reflect varied strategies that range from portfolio breadth and lifecycle management to targeted innovation and partnerships. Large biopharmaceutical firms are consolidating their foothold in preventive care by leveraging established commercial infrastructures and investing in long-term evidence-generation programs. These players often pursue broad-label strategies, coupled with patient-support initiatives and integrated services that facilitate adherence and specialty dispensing.

Niche and mid-sized companies are concentrating on differentiated mechanisms of action, convenience of administration, and specific patient subpopulations where clinical differentiation can justify premium positioning. Partnerships between innovators and contract manufacturing or distribution partners are increasingly common, enabling agility in supply-chain scaling while allowing smaller firms to focus on clinical development and market access strategies. Strategic alliances between pharmaceutical companies and digital-health vendors are also on the rise, reflecting a shift toward bundled propositions that combine medication with adherence and monitoring tools.

Across the competitive landscape, companies that demonstrate a clear evidence generation roadmap, a flexible pricing approach, and strong relationships with specialty care networks and payers tend to secure favorable access outcomes. In addition, organizations that proactively manage regimen-switching patterns, optimize patient initiation pathways, and support clinicians with concise, outcome-focused datasets are better positioned to achieve durable uptake. Observing these strategic behaviors provides a practical template for companies aiming to refine their market entry or expansion approaches.

Actionable strategic recommendations that combine evidence generation, digital-enabled support, and resilient commercial models to secure durable access and uptake

Industry leaders seeking to capture sustainable value in migraine therapeutics should pursue multifaceted actions that integrate clinical evidence, payer engagement, and operational resilience. First, prioritize generation of patient-centered real-world data that complements randomized controlled trial results and directly addresses payer questions about durability of effect, safety in heterogeneous populations, and health-economic outcomes. Such evidence will underpin value-based conversations and help secure favorable formulary positioning.

Second, develop differentiated patient support and adherence programs that leverage digital tools to reduce barriers to initiation and continuation of therapy. Integrated care pathways that combine clinician education, remote monitoring, and streamlined access processes can materially improve persistence and patient satisfaction, thereby reinforcing clinical and economic value propositions. Third, build flexible commercial strategies that account for regional regulatory variation and tariff-related supply-chain risk; this includes diversifying manufacturing and distribution partners, investing in local regulatory expertise, and incorporating tariff scenarios into scenario planning.

Finally, pursue collaborative arrangements with payers and health systems, such as outcomes-based agreements or risk-sharing models, where feasible and supported by robust outcomes measurement. Such partnerships can accelerate access while aligning incentives around measurable patient benefit. Taken together, these actions support a resilient, evidence-driven approach to market entry and lifecycle management that balances short-term uptake with long-term value realization.

A rigorous, multi-source research methodology combining primary stakeholder interviews, systematic literature review, and cross-validated analytical techniques to produce actionable insights

The research methodology underpinning this analysis integrates multiple evidence streams to ensure robust, triangulated insights. Primary research included structured interviews with clinicians, payers, procurement specialists, and industry executives to capture lived experience with therapeutic choices, formulary decision drivers, and operational barriers. Secondary research encompassed a systematic review of peer-reviewed literature, regulatory documents, clinical trial registries, and public company disclosures to validate clinical profiles, safety signals, and product pipelines.

Analytical techniques involved cross-validation of qualitative inputs against secondary sources, thematic coding of interview content to identify recurring barriers and enablers, and the development of segmentation matrices that map clinical utility to commercial levers. Supply-chain and tariff impact assessments drew on customs classifications, logistics workflows, and expert consultations to model potential operational responses without attempting to forecast specific market figures. Quality assurance processes included peer review by therapeutic area experts and reconciliation of conflicting data points through follow-up interviews.

By synthesizing diverse evidence streams and applying transparent analytic logic, the methodology provides a defensible basis for the insights and recommendations presented. The approach balances depth and practicality, designed to inform decision makers who require actionable intelligence rather than high-level summaries alone.

A concise conclusion synthesizing innovation, access dynamics, and strategic priorities that define success in the contemporary migraine therapeutics arena

In closing, the migraine therapeutics landscape is characterized by meaningful scientific progress, evolving commercial models, and heightened expectations from payers and patients for measurable outcomes. The convergence of biologic preventive agents, targeted small molecules for acute care, and supportive digital tools reshapes standards of care and compels stakeholders to adopt more sophisticated value demonstration strategies. Success in this environment requires a clear alignment between clinical differentiation, evidence generation, and pragmatic commercial execution.

Manufacturers and investors should view the current period as one of opportunity that rewards disciplined evidence planning, nimble supply-chain strategies, and constructive payer engagement. Meanwhile, clinicians and patient advocates benefit from an expanding therapeutic toolkit that can be tailored to individual patient preferences and tolerability requirements. As the sector evolves, sustained emphasis on real-world outcomes, adherence support, and collaborative access models will determine which innovations translate into meaningful improvements in patient care.

Taken together, the insights in this executive summary provide a platform for immediate action and longer-term planning. Stakeholders who leverage these perspectives to refine development strategies, optimize market access approaches, and strengthen operational resilience will be best positioned to capture the clinical and commercial potential arising from ongoing innovation in migraine treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid payer adoption and reimbursement challenges for CGRP monoclonal antibody therapies in migraine treatment
  • 5.2. Growing market penetration of gepant oral CGRP receptor antagonists for acute migraine relief and prevention
  • 5.3. Surge in real-world evidence generation influencing payer coverage and formulary decisions for novel migraine drugs
  • 5.4. Introduction of fast-acting 5HT1F receptor agonists offering alternative acute migraine relief for triptan nonresponders
  • 5.5. Integration of digital therapeutics and wearable monitoring platforms into personalized chronic migraine management plans
  • 5.6. Advancements in noninvasive neurostimulation devices expanding nonpharmacological options for refractory migraine sufferers
  • 5.7. Development of biosimilar versions of high-cost migraine biologics poised to disrupt pricing and market competition
  • 5.8. Implementation of value-based contracting and outcomes-based agreements for high-cost migraine therapies with payers
  • 5.9. Focus on health equity initiatives to improve access and affordability of advanced migraine treatments in underserved populations
  • 5.10. Expansion of telemedicine platforms accelerating virtual diagnosis, remote management, and patient support in migraine care

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Migraine Drugs Market, by Drug Class

  • 8.1. Cgrp Monoclonal Antibodies
    • 8.1.1. Eptinezumab
    • 8.1.2. Erenumab
    • 8.1.3. Fremanezumab
    • 8.1.4. Galcanezumab
  • 8.2. Ditans
    • 8.2.1. Lasmiditan
  • 8.3. Ergot Derivatives
    • 8.3.1. Dihydroergotamine
    • 8.3.2. Ergotamine
  • 8.4. Gepants
    • 8.4.1. Atogepant
    • 8.4.2. Rimegepant
    • 8.4.3. Ubrogepant
  • 8.5. Nsaids
    • 8.5.1. Diclofenac
    • 8.5.2. Ibuprofen
    • 8.5.3. Naproxen
  • 8.6. Triptans
    • 8.6.1. Almotriptan
    • 8.6.2. Eletriptan
    • 8.6.3. Frovatriptan
    • 8.6.4. Naratriptan
    • 8.6.5. Rizatriptan
    • 8.6.6. Sumatriptan
    • 8.6.7. Zolmitriptan

9. Migraine Drugs Market, by Route Of Administration

  • 9.1. Injectable
    • 9.1.1. Intravenous
    • 9.1.2. Subcutaneous
  • 9.2. Nasal
  • 9.3. Oral
    • 9.3.1. Capsule
    • 9.3.2. Tablet
  • 9.4. Topical
  • 9.5. Transdermal

10. Migraine Drugs Market, by Distribution Channel

  • 10.1. Offline
  • 10.2. Online

11. Migraine Drugs Market, by Indication

  • 11.1. Acute Treatment
  • 11.2. Preventive Treatment

12. Migraine Drugs Market, by Patient Age Group

  • 12.1. Adult
  • 12.2. Pediatric
    • 12.2.1. Adolescents
    • 12.2.2. Children
    • 12.2.3. Neonates

13. Migraine Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Migraine Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Migraine Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. AbbVie Inc.
    • 16.3.2. Amgen Inc.
    • 16.3.3. Novartis AG
    • 16.3.4. Eli Lilly and Company
    • 16.3.5. H. Lundbeck A/S
    • 16.3.6. Biohaven Pharmaceutical Holding Company Ltd.
    • 16.3.7. Teva Pharmaceutical Industries Ltd.
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Merck & Co., Inc.
    • 16.3.10. GlaxoSmithKline plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. MIGRAINE DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. MIGRAINE DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MIGRAINE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MIGRAINE DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY EPTINEZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERENUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FREMANEZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GALCANEZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DITANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY LASMIDITAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DIHYDROERGOTAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ERGOTAMINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ATOGEPANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIMEGEPANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY UBROGEPANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DICLOFENAC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY IBUPROFEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NAPROXEN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ALMOTRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ELETRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY FROVATRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NARATRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY RIZATRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUMATRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ZOLMITRIPTAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CAPSULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TABLET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ACUTE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PREVENTIVE TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY NEONATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL MIGRAINE DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 300. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 301. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 302. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 303. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 304. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS MIGRAINE DRUGS MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 329. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 330. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 331. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 332. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 333. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 334. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY CGRP MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 335. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2018-2024 (USD MILLION)
  • TABLE 336. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY DITANS, 2025-2032 (USD MILLION)
  • TABLE 337. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2018-2024 (USD MILLION)
  • TABLE 338. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ERGOT DERIVATIVES, 2025-2032 (USD MILLION)
  • TABLE 339. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2018-2024 (USD MILLION)
  • TABLE 340. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY GEPANTS, 2025-2032 (USD MILLION)
  • TABLE 341. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2018-2024 (USD MILLION)
  • TABLE 342. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY NSAIDS, 2025-2032 (USD MILLION)
  • TABLE 343. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2018-2024 (USD MILLION)
  • TABLE 344. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY TRIPTANS, 2025-2032 (USD MILLION)
  • TABLE 345. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 346. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 347. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2018-2024 (USD MILLION)
  • TABLE 348. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY INJECTABLE, 2025-2032 (USD MILLION)
  • TABLE 349. NORTH AMERICA MIGRAINE DRUGS MARKET SIZE, BY ORAL, 2018-2024 (USD